← Eichor
Study identifier: NCT05590637 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Comparing Antipsychotic Medications in LBD Over Time

Condition: Parkinson's Disease Psychosis · Dementia With Lewy Bodies  ·  Sponsor: The University of Texas Health Science Center at San Antonio

PhasePhase 4
Planned participants94
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).

This description comes directly from the study's public registry record.

Talk to the study team

Carolyn Paiz, BS  ·  210-450-8830  ·  paizc@uthscsa.edu

Always discuss trial participation with your own doctor first.

Locations (2)

University Health SystemSan Antonio, Texas, United StatesRecruiting
UT Health Science Center - San AntonioSan Antonio, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05590637